Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DICER: Dostarlimab + Chemoradiation for SCNECC
NCT07336147Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in Small cell neuroendocrine carcinoma of the cervix (SCNECC), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
Small cell neuroendocrine carcinoma of the cervix (SCNECC)
Beyond the preview
Go deeper on NCT07336147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336147.